Stay updated on Epacadostat & Nivolumab Combo in Immune Therapies Clinical Trial
Sign up to get notified when there's something new on the Epacadostat & Nivolumab Combo in Immune Therapies Clinical Trial page.

Latest updates to the Epacadostat & Nivolumab Combo in Immune Therapies Clinical Trial page
- Check3 days agoChange DetectedNo textual changes were captured for this page in the provided data.SummaryDifference0.0%

- Check10 days agoChange DetectedThe study record page was updated to Revision: v3.6.4, indicating a new release of the page. This update appears to be internal maintenance rather than a modification to study content.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedA revision label on the study page was updated from v3.6.2 to v3.6.3, indicating an administrative update to the ClinicalTrials.gov page. It does not alter the study details, enrollment, or eligibility.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page now displays revision v3.6.2, replacing the previous v3.6.0. This indicates a page-build update rather than a change to study details.SummaryDifference0.0%

- Check53 days agoChange DetectedNew navigation and help sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the recruitment status now indicates no longer looking for participants. A formatting adjustment for Intervention/Treatment and an update to the page revision (v3.6.0) are also included.SummaryDifference0.4%

- Check60 days agoChange DetectedThe page’s revision label updates from v3.5.4 to v3.5.5, signaling a backend or frontend update. This change reflects an upgrade to the page framework rather than new or altered study information.SummaryDifference0.0%

Stay in the know with updates to Epacadostat & Nivolumab Combo in Immune Therapies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Epacadostat & Nivolumab Combo in Immune Therapies Clinical Trial page.